This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Peak Bio マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

CEO（最高経営責任者

Peak Bio CEOがいない、あるいは彼らに関するデータがない。

This company has been acquired

Peak Bio マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Peak Bio, Inc. Announces Appointment of Sandip Patel as Director and Chairperson of Audit Committee

Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee

Recent updates

Peak Bio Files Form 15

Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.

Peak Bio, Inc. Announces Appointment of Sandip Patel as Director and Chairperson of Audit Committee

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. announced delayed annual 10-K filing

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee

Peak Bio, Inc. announced that it expects to receive $100 million in funding from White Lion Capital Llc

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc.(OTCPK:PKBO) dropped from S&P TMI Index

Peak Bio, Inc.(OTCPK:PKBO) dropped from NASDAQ Composite Index

Peak Bio Receives the Determination Letter from the Panel to Delist the Company’s Common Stock from Nasdaq

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. announced that it has received $100 million in funding from White Lion Capital Llc

Peak Bio Receives Non-Compliance Notice from Nasdaq

CEO（最高経営責任者

This company has been acquired

Peak Bio マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Peak Bio, Inc. Announces Appointment of Sandip Patel as Director and Chairperson of Audit Committee

Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee

Recent updates

Peak Bio Files Form 15

Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.

Peak Bio, Inc. Announces Appointment of Sandip Patel as Director and Chairperson of Audit Committee

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. announced delayed annual 10-K filing

Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO).

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. Appoints Michael Friedman to Board of Directors and Member of Audit Committee and Compensation Committee

Peak Bio, Inc. announced that it expects to receive $100 million in funding from White Lion Capital Llc

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc.(OTCPK:PKBO) dropped from S&P TMI Index

Peak Bio, Inc.(OTCPK:PKBO) dropped from NASDAQ Composite Index

Peak Bio Receives the Determination Letter from the Panel to Delist the Company’s Common Stock from Nasdaq

Peak Bio, Inc. announced delayed 10-Q filing

Peak Bio, Inc. announced that it has received $100 million in funding from White Lion Capital Llc

Peak Bio Receives Non-Compliance Notice from Nasdaq

CEO（最高経営責任者

マネジメント基準チェック /04